Humacyte Inc
NASDAQ:HUMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Humacyte Inc
NASDAQ:HUMA
|
US |
|
Zhejiang Zone-King Environmental Sci&Tech Co Ltd
SSE:688701
|
CN |
|
S
|
SFK Construction Holdings Ltd
HKEX:1447
|
HK |
Humacyte Inc
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Symvess launch: Humacyte said U.S. commercialization of Symvess is still early but improving, with 27 hospitals ordering the product and most of them reordering.
Pricing helped: Management said the new $17,000 price point has been well received, improved VAC approval rates to above 70%, and made hospitals more willing to stock and use the product.
International push: The company highlighted a $1.475 million purchase commitment in Saudi Arabia and a marketing authorization filing in Israel as early steps toward overseas commercialization.
Pipeline progress: Humacyte said it is on track for a dialysis access interim readout by early June 2026 and plans a supplemental BLA in the second half of 2026 if results are positive.
Cash and financing: Year-end cash was $50.5 million, and the company added new financing after quarter-end, including $18.4 million from a direct offering, $4.6 million from an aftermarket sale, and a $77.5 million credit facility.
